8-acetyl-3-methylimidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑四嗪类
• 英文名称: 8-acetyl-3-methylimidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one
• 英文别名: temozolomide；8-Acetyl-3-methylimidazo[5,1-d][1,2,3,5]tetrazin-4-one
• 化学式: C₇H₇N₅O₂
• 分子量: 193.165
• InChiKey: QXYCTGXCOQXVRU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  79.9
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  1-(5-amino-1H-imidazol-4-yl)ethan-1-one 在 溶剂黄146 、 三乙胺 、 lithium chloride 作用下， 以 水 、 乙腈 为溶剂， 反应 6.0h， 生成 8-acetyl-3-methylimidazo[5,1-d][1,2,3,5]tetrazin-4(3H)-one
  参考文献：
  名称：

  [EN] IMIDAZOTETRAZINE COMPOUNDS
  [FR] COMPOSÉS D'IMIDAZOTÉTRAZINE

  摘要：

  新的合成方法提供了对咪唑四唑的C8位置以前未探索功能的访问。通过合成和评估一系列具有不同水稳定性（从0.5到40小时）的化合物，基于C8取代基的Hammett常数建立了咪唑四唑水解稳定性的预测模型。鉴定了具有活性的化合物，对一系列GBM细胞系具有活性，具有适当的水解和代谢稳定性，并且脑血清比例相对于TMZ显著升高，导致较低的血液毒性剖面和在GBM小鼠模型中优于TMZ的活性。

  公开号：

  WO2020033880A1

文献信息

• Tunable Stability of Imidazotetrazines Leads to a Potent Compound for Glioblastoma
  作者：Riley L. Svec、Lucia Furiassi、Christine G. Skibinski、Timothy M. Fan、Gregory J. Riggins、Paul J. Hergenrother

  DOI：10.1021/acschembio.8b00864

  日期：2018.11.16

  (such as aliphatic, ketone, halogen, and aryl groups) at the C8 position of imidazotetrazines. Through synthesis and evaluation of a suite of compounds with a range of aqueous stabilities (from 0.5 to 40 h), we derive a predictive model for imidazotetrazine hydrolytic stability based on the Hammett constant of the C8 substituent. Promising compounds were identified that possess activity against a panel

  即使在个性化医学和免疫疗法的时代，替莫唑胺（TMZ），一种小分子DNA烷基化剂，仍然是胶质母细胞瘤（GBM）的护理标准。TMZ具有异常的作用方式，可通过体内水解自发转化为其活性成分。尽管TMZ已获得FDA批准长达20年之久，但对于肿瘤表达抗性酶MGMT并通过骨髓抑制引起全身毒性的患者，TMZ几乎没有益处。TMZ于1984年首次合成，但由于TMZ的化学敏感性，无法获得某些关键衍生物，这排除了对咪唑四嗪结构与生物活性之间联系的广泛探索。在这里，我们试图辨别咪唑并四嗪的水解稳定性和抗癌活性之间的关系，目的是确定前药激活的最佳时机，并通过增加血脑屏障的渗透性来开发具有增强功效的合适化合物。这项工作需要开发新的合成方法，以便在咪唑并四嗪的C8位上获得以前未开发的功能（例如脂族，酮，卤素和芳基）。通过合成和评估一系列具有一定范围水稳定性（0.5至40 h）的化合物，我们基于C8取代基的Hammett常
• Methods and Intermediates for the Synthesis of 4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]tetrazines
  申请人：Hummersone Marc Geoffery

  公开号：US20130012706A1

  公开（公告）日：2013-01-10

  The present invention provides a compound of general formula (II), or a salt or solvate thereof: wherein A is independently -A 1 , -A 2 , -A 3 , -A 4 , -A 5 , -A 6 , or -A 7 , wherein: -A 1 is independently C 5-12 heteroaryl, and is optionally substituted; -A 2 is independently thioamido or substituted thioamido; -A 3 is independently imidamido, substituted imidamido, N-hydroxyimidamido, or substituted N-hydroxyimidamido; -A 4 is independently hydroxamic acid or hydroxamate; -A 5 is independently carboxamide or substituted carboxamide; -A 6 is independently aliphatic C 2-6 alkenyl, and is optionally substituted; and -A 7 is independently carboxy or C 1-4 alkyl-carboxylate; and its use in the synthesis of temozolomide and analogues thereof.

  本发明提供一种通式（II）的化合物或其盐或溶剂化物：其中A独立地为-A1，-A2，-A3，-A4，-A5，-A6或-A7，其中：-A1独立地为C5-12杂环芳基，并且可以被取代；-A2独立地为硫酰胺基或取代硫酰胺基；-A3独立地为咪唑酰胺基，取代咪唑酰胺基，N-羟基咪唑酰胺基或取代N-羟基咪唑酰胺基；-A4独立地为羟肟酸或羟肟酸盐；-A5独立地为羧酰胺或取代羧酰胺；-A6独立地为脂肪族C2-6烯基，并且可以被取代；-A7独立地为羧基或C1-4烷基羧酸盐；以及其在替莫唑胺及其类似物的合成中的用途。
• PHARMACEUTICAL COMBINATIONS COMPRISING FOR THE TREATMENT OF SPECIFIC CANCERS
  申请人：Chapman Mark

  公开号：US20120071435A1

  公开（公告）日：2012-03-22

  The present invention relates to the field of oncology and provides compositions and methods for treating specific cancers, including non small cell lung cancer, breast cancer, thyroid cancer, pancreatic cancer, colon cancer, melanoma, hepatoma and adenocarcinoma. Particularly, compositions and methods involving administration, either simultaneously or sequentially, of pharmaceutical combinations comprising (S)—N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide with other compounds, to patients suffering from cancer are described.
• DRUG DELIVERY OF TEMOZOLOMIDE FOR SYSTEMIC BASED TREATMENT OF CANCER
  申请人：Patil Rameshwar

  公开号：US20120328555A1

  公开（公告）日：2012-12-27

  The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety. The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety.
• PHARMACEUTICAL COMBINATIONS FOR TREATMENT OF SPECIFIC CANCERS
  申请人：ARDEA BIOSCIENCES, INC.

  公开号：US20140080783A1

  公开（公告）日：2014-03-20

  The present invention relates to the field of oncology and provides compositions and methods for treating specific cancers, including non small cell lung cancer, breast cancer, thyroid cancer, pancreatic cancer, colon cancer, melanoma, hepatoma and adenocarcinoma. Particularly, compositions and methods involving administration, either simultaneously or sequentially, of pharmaceutical combinations comprising (S)—N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide with other compounds, to patients suffering from cancer are described.